Showing results (181-190 of 253) with videos related to
Sort By:
Pageof 26
The American Journal of Cardiology|June 23, 2009
Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)Jennifer G Robinson, Christie M Ballantyne, Scott M Grundy, et al.Cardiovascular Diabetology|April 8, 2018
Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuriaGemma E Currie, Bernt Johan von Scholten, Sheon Mary, et al.European Journal of Endocrinology|April 23, 2008
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetesSøren S Lund, Lise Tarnow, Coen D A Stehouwer, et al.Circulation|December 28, 2006
Subclinical coronary and aortic atherosclerosis detected by magnetic resonance imaging in type 1 diabetes with and without diabetic nephropathyWon Yong Kim, Anne Sofie Astrup, Matthias Stuber, et al.The Lancet. Diabetes & Endocrinology|January 18, 2016
Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trialHiddo J L Heerspink, Frederik Persson, Barry M Brenner, et al.Plos One|March 3, 2021
Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuriaSigne Abitz Winther, Jens Christian Øllgaard, Tine Willum Hansen, et al.Diabetes Care|April 13, 2018
Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and MicroalbuminuriaDaniel G K Rasmussen, Tine W Hansen, Bernt J von Scholten, et al.Journal of the American Society of Nephrology : JASN|April 6, 2007
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trialWouter B A Eijkelkamp, Zhongxin Zhang, Giuseppe Remuzzi, et al.Kidney International|April 1, 2011
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal functionFrank A Holtkamp, Dick de Zeeuw, Merlin C Thomas, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|January 16, 2009
Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study designHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.Pageof 26